Feasibility Study for Fibroblast Autologous Skin Grafts
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01964859|
Recruitment Status : Recruiting
First Posted : October 17, 2013
Last Update Posted : June 10, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Wounds and Injuries||Biological: autologous skin fibroblasts||Phase 2|
To change the skin identity investigators propose to take skin cells from a person's own sole or palm (these are called "autologous skin fibroblasts"), multiply them in the lab, inject the cells (now called a "graft") back into the same person but at a different site of skin like the buttock, and then eventually remove the injected cells to see if they caused the skin to change.
Investigators hope that information from this study will help with problems like skin break-down in patients with amputations and prosthetics. The skin at their stump was not meant to withstand the pressure and friction of prosthetics and this study is the first step in trying to convert stump skin to palm/sole-like skin.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Masking Description:||Sites are labeled as A, B and C and masked for outcomes assessors-- but these are all in the same subject.|
|Primary Purpose:||Basic Science|
|Official Title:||Feasibility Study for Fibroblast Autologous Skin Grafts: Biopsy of Skin Fibroblasts, Expansion in Cell Therapy Core, Topical Injection of Fibroblasts, and Subsequent Removal of Graft for Laboratory Studies.|
|Actual Study Start Date :||January 7, 2015|
|Estimated Primary Completion Date :||December 2023|
|Estimated Study Completion Date :||December 2024|
Experimental: autologous skin fibroblasts
we are comparing 3 injection sites in the same individual
Biological: autologous skin fibroblasts
- Cytoplasmic size increase [ Time Frame: 6 months ]Volar keratinocytes have larger area of the cytoplasm. We will quantitate the area of cytoplasm of non-volar keratinocytes to see if they increase selectively with volar fibroblasts as opposed to other fibroblasts injections or vehicle. The change in the area of cytoplasm of non-volar keratinocytes will be measured. The units of this measurement are a ratio of cytoplasmic area to total cellular area as a control.
- Durometer reading [ Time Frame: 6 months ]Durometers measure the firmness of the skin. We will measure all sites to see if the area injected with volar fibroblasts is more firm. The units of measurement is in Durometer Units.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- May be male or female
- Must be between 18 years and 65 years of age
- In the opinion of the investigator, must be medically able to undergo the administration of study material determined by laboratory tests obtained within 7 days before baseline for which the investigator identified no clinically significant abnormality.
- Be able to comprehend the informed consent document and provide consent for participation
Females of childbearing potential must:
- have a negative pregnancy test at screening
- agree to not become pregnant or breastfeed for the period of the study through 1 month after completion of the study
- be willing to use a reliable form of contraception during the study
- Have healthy skin as determined by the PI or study Nurse Practitioner.
- Be willing and able to comply with the scheduled visits, biopsy/injection procedures, wound care instructions treatment plan, and other study procedures for the duration of the study.
- Having received any investigational drug within 30 days prior to study entry
- An allergy history to any study materials including local anesthetic, dimethyl sulfoxide, human albumin, or bovine constituents, or hetastarch
- Pregnant, lactating, or trying to become pregnant
- A history of keloid formation
- An active nonhealing wound
- Having a significant medical history that the investigator feels is not safe for study participation (for example, some forms of autoimmune conditions, metastatic cancer, infectious diseases such as HIV, Human T-lymphotropic virus (HTLV) I/II, Hepatitis B, Hepatitis C). Biopsies taken from individuals with infections that are not allowed to enter the cell therapy core will make it such that these individuals cannot participate.
- Specifically we will exclude those with autoimmune diseases affecting the skin such as lupus.
- Having current skin diseases (i.e. extreme and active eczema, psoriasis, lichen planus) that the investigator feels is not safe for study participation
- A diagnosis of uncontrolled diabetes
- Active smoker during the study
- We will also exclude those who are on chronic immunosuppressive therapies such as oral steroids, but also those on chronic topical steroids in the area of investigation.
- Known bovine or meat sensitivity or severe allergies manifested by anaphylaxis to any product
- Known bleeding disorder
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01964859
|Contact: Ruizhi Wangemail@example.com|
|United States, Maryland|
|Johns Hopkins School of Medicine, Dermatology Department||Recruiting|
|Baltimore, Maryland, United States, 21287|
|Contact: Sherry Leung 410-502-7546 firstname.lastname@example.org|
|Principal Investigator: Luis Garza, MD, PhD|
|Principal Investigator:||Luis Garza, MD, PhD||Department of Dermatology, Johns Hopkins School of Medicine|
|Responsible Party:||Johns Hopkins University|
|Other Study ID Numbers:||
1R01AR064297-01A1 ( U.S. NIH Grant/Contract )
|First Posted:||October 17, 2013 Key Record Dates|
|Last Update Posted:||June 10, 2022|
|Last Verified:||June 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Per the requirements of the journal in which we finally publish.|
wounds and injuries
Wounds and Injuries